GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the ...

Belimumab bested placebo in terms of SRI-4 response among patients treated for less than 2 years (OR = 1.38; P = .0219), and in those treated for 2 years or greater (OR = 1.85; P < .0001).

British pharmaceutical company GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, has partnered with HGS on Benlysta since 2006. The Lupus Foundation of America ...

December 18, 2019 – GSK announces BLISS–LN achieves primary endpoint and all major secondary endpoints in the phase 3 study of Benlysta in patients with lupus nephritis. December 17, 2020 – FDA ...

The trial, which GlaxoSmithKline announced in a recent press release, will also evaluate Benlysta's safety profile; the drug has not been approved to treat vasculitis by any regulatory body, yet.

London-based GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, has partnered with Maryland-based Human Genome Sciences on Benlysta’s development since 2006.

An estimated 5000-10,000 children in the United States are living with SLE. Belimumab is a B-lymphocyte stimulator–specific inhibitor approved for the treatment of active SLE and active lupus ...

The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy ...